Bile duct cancer combo trial halted early
Disease control
Terminated
This study tested a new drug combination (GEN-001 plus pembrolizumab) in 10 adults with advanced bile duct cancer that had stopped responding to standard treatments. The goal was to see if the combination was safe and could shrink tumors. The trial was terminated early, so result…
Phase: PHASE2 • Sponsor: Genome & Company • Aim: Disease control
Last updated May 04, 2026 16:21 UTC